Research into teenage and young adults’ cancer has made slower progress than for any other age group. One reason is that many clinical trials exclude patients under 18 – without medical justification.
To confront this problem, the Working Group on Fostering Age Inclusive Research (or FAIR Trials) was established in 2017 by the ACCELERATE Forum. Made up of 15 experts from Academia, Industry and Parents/Patients advocacy, the group aims to raise awareness and promote change.
Latest Endorsements. Spring 2020 has brought more statements of support for age inclusive research
- Sarcoma Patient Euronet (SPAEN) calls on researchers, regulators, and members of ethics committees to support the ACCELERATE Fostering Age Inclusive Research (FAIR) Working Group commitment to consider adolescent inclusion in adult research when relevant as a trial methodology which offers earlier access to investigational and approved medicines for adolescent patients. Read the full statement and a blog on the SPAEN conference.
- Sarcoma UK supports the Fostering Age Inclusive Research (FAIR) Trials initiative and calls on researchers, regulators, and members of ethics committees to consider adolescent inclusion in adult research when relevant. Find out more about Sarcoma UK endorsement of FAIR Trials.
- Ecancer, Applied Clinical Trials and Touch Oncology have published the FAIR Trials press release. Read the full press release on the websites of ecancer, Applied Clinical Trials , Touch Oncology and also Touch Oncology Twitter account.
Departure Lounge. Blog relating visit to the Sarcoma Euronet conference in Milan, prior to the COVID-19 lockdown.
Spring 2019 has brought statements of support for age inclusive research from three major international health forums.
‘The European Medicines Agency (EMA) and its Paediatric Committee (PDCO) follow closely and with great interest the Accelerate’s FAIR (Foster Age-Inclusive Research) initiative… We sincerely appreciate your efforts and hope we can all continue to work together to improve the development of medicines for children with cancer.’
‘As part of the responsibility to provide better medicines for children, the European Forum for Good Clinical Practice strongly recommends:
That researchers, regulators, and members of ethics committees weigh the totality of physiologic, pathologic, and other disease specific evidence to consider adolescent inclusion in adult research and vice versa – young adults as an extension population in paediatric/adolescent studies – when relevant as a trial methodology to facilitate earlier access to investigational and approved medicines for adolescent patients.’
‘The US Food and Drugs Administration recommends the inclusion of adolescent patients in disease- and target-appropriate adult oncology clinical trials to enable earlier access to investigational and approved drugs for adolescent patients with cancer.’
Join the conversation on Twitter: #ACCELERATEplatform | #FAIRtrials